Patrick Forde: Interesting ODAC for future perioperative trial designs

ASCO’s rapid guideline update for the management of stage III NSCLC

Stephen Liu: Novel epigenomic cfDNA approach in diagnosis of EGFR mutant NSCLC

Gevorg Tamamyan: I urge Agenus to consider Armenia as the first country to register BOT/BAL combination

ESMO Living Guideline on Oncogene-Addicted Metastatic NSCLC

Clinical Utility of Pre-surgical ctDNA Detection in Early Stage NSCLC

Osimertinib could change the standard of care for EGFR-mutant NSCLC

Gerard Walls: ctDNA, a future tool for radiation therapy personalization in lung cancer?

Francesco Cortiula: What evidences for the treatment of patients with stage III NSCLC excluded from trials?

Tanja Obradovic: Choosing immunotherapy treatment for early resectable NSCLC